GBT Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Global Blood Therapeutics (GBT) Tops Q2 EPS by 7c
August 3, 2021 4:46 PM EDTGlobal Blood Therapeutics (NASDAQ: GBT) reported Q2 EPS of ($1.12), $0.07 better than the analyst estimate of ($1.19). Revenue for the quarter came in at $47.6 million versus the consensus estimate of $43.84 million.
For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.
... More


